EP2833863A1 - Novel oligosaccharide compounds and the cosmetic use thereof - Google Patents
Novel oligosaccharide compounds and the cosmetic use thereofInfo
- Publication number
- EP2833863A1 EP2833863A1 EP13720456.6A EP13720456A EP2833863A1 EP 2833863 A1 EP2833863 A1 EP 2833863A1 EP 13720456 A EP13720456 A EP 13720456A EP 2833863 A1 EP2833863 A1 EP 2833863A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cutaneous
- alteration
- equal
- capillary
- daltons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 61
- 239000002537 cosmetic Substances 0.000 title claims description 15
- -1 oligosaccharide compounds Chemical class 0.000 title description 6
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 58
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 25
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 25
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 25
- 239000000470 constituent Substances 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 230000004075 alteration Effects 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 32
- 238000006731 degradation reaction Methods 0.000 claims description 27
- 230000015556 catabolic process Effects 0.000 claims description 23
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 22
- 241000196251 Ulva arasakii Species 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 16
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 12
- 230000008520 organization Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 10
- 238000005119 centrifugation Methods 0.000 claims description 9
- 230000006870 function Effects 0.000 claims description 9
- 230000032683 aging Effects 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 238000001784 detoxification Methods 0.000 claims description 8
- 230000004089 microcirculation Effects 0.000 claims description 8
- 230000037303 wrinkles Effects 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 230000017423 tissue regeneration Effects 0.000 claims description 7
- 241001474374 Blennius Species 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 238000000889 atomisation Methods 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 230000000694 effects Effects 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 210000002950 fibroblast Anatomy 0.000 description 16
- 150000004676 glycans Chemical class 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 229920001282 polysaccharide Polymers 0.000 description 15
- 239000005017 polysaccharide Substances 0.000 description 15
- 108010035532 Collagen Proteins 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 8
- 201000004384 Alopecia Diseases 0.000 description 8
- 230000003676 hair loss Effects 0.000 description 8
- 229920002674 hyaluronan Polymers 0.000 description 8
- 229960003160 hyaluronic acid Drugs 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 206010013786 Dry skin Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000037336 dry skin Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 208000024963 hair loss Diseases 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229940097043 glucuronic acid Drugs 0.000 description 5
- 238000007373 indentation Methods 0.000 description 5
- 238000007634 remodeling Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 229940031518 ulva lactuca extract Drugs 0.000 description 4
- 108091022879 ADAMTS Proteins 0.000 description 3
- 102000029750 ADAMTS Human genes 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
- 101000945075 Homo sapiens Collectrin Proteins 0.000 description 3
- 101000934320 Homo sapiens Cyclin-A2 Proteins 0.000 description 3
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 108010003425 hyaluronan-mediated motility receptor Proteins 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
- 230000009452 underexpressoin Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- IGHBXJSNZCFXNK-UHFFFAOYSA-N 4-chloro-7-nitrobenzofurazan Chemical compound [O-][N+](=O)C1=CC=C(Cl)C2=NON=C12 IGHBXJSNZCFXNK-UHFFFAOYSA-N 0.000 description 2
- 208000035484 Cellulite Diseases 0.000 description 2
- 102100033635 Collectrin Human genes 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102100025191 Cyclin-A2 Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010049752 Peau d'orange Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000196252 Ulva Species 0.000 description 2
- 241000196259 Ulva pertusa Species 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 238000000569 multi-angle light scattering Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 230000037393 skin firmness Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 230000010736 Chelating Activity Effects 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 241000196246 Ulvaceae Species 0.000 description 1
- 241000196247 Ulvales Species 0.000 description 1
- 229920002000 Xyloglucan Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000000089 arabinosyl group Chemical class C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000007813 chromatographic assay Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
Definitions
- the present invention relates to novel oligosaccharide compounds extracted from the green alga Ulva Lactuca, a cosmetic composition comprising one or more of these compounds and their pharmaceutically acceptable salts, and the use of these compounds or this composition to maintain the integrity and concentration of the constituent molecules of the extracellular matrix.
- Ulva Lactuca or sea lettuce
- Ulva Lactuca is a marine green, nitrophilous algae of the family Ulvaceae and the order of Ulvales.
- the first family consists of a sulfated rhamnoglycuronan referred to as ulvan (Ray and Lahaye, 1995). It is soluble in water and differs from other polysaccharides contained in the wall of the seaweed by its content of rhamnose (30 to 50%), glucuronic acid (10 to 20%) and sulfate (16 to 19%) ).
- the second family consists of? - (1,4) -D-xyloglucans and? - (1,4) -D-glucuronans.
- the third family consists of amorphous cellulose.
- the patent application WO-A-2008/1461 16 describes the use of Ulva Lactuca or extracts of this alga for the preparation of cosmetic compositions having a triple action on the dermis: stimulation of the proliferation of fibroblasts, stimulation of elastin production and stimulation of the synthesis of type I collagen. Nevertheless, no indication is provided in this patent application concerning the extraction process used to prepare the extract of Ulva Lactuca, so that it is impossible to determine the exact composition. On the other hand, the Ulva lactuca extract only acts on the proliferation of fibroblasts. No stimulation of collagen and hyaluronic acid synthesis is associated with the use of Ulva lactuca extract alone.
- the skin is constantly subject to many intrinsic and / or extrinsic stresses such as UV, pollution, heat, cold, various pathologies, injuries, inflammation, aging or hormonal activity. .
- the skin ends up being damaged by the succession of these aggressions, which results in particular in an alteration of the cutaneous architecture leading to an alteration of structures and cutaneous functions.
- the main factors responsible for this disorganization of the extracellular matrix are thus the decrease of the biosynthesis and / or the increase of the degradation of these constituent molecules but also the bad disposition of these compounds within this matrix.
- the oligosaccharides thus prepared make it possible to induce the biosynthesis and / or the organization of the constituent molecules of the extracellular matrix, and / or to reduce their degradation, thus allowing the introduction and maintaining the architecture of the extracellular matrix and thus preventing and / or treating the signs of intrinsic and / or extrinsic cutaneous and / or capillary aging, in particular the alteration of cutaneous and / or capillary structures and functions, alteration of tissue regeneration, tissue relaxation, alteration of cutaneous and / or capillary microcirculation, alteration of cutaneous detoxification, loss of uniformity, brightness and shine of hue (dermal) and / or capillary), the alteration of the cutaneous surface texture (appearance of wrinkles, puffiness, dry skin, etc.) and / or capillary (brittle hair), and the alteration of the cutaneous and / or capillary architecture (inducing in particular the hair loss).
- the subject of the present invention is therefore an oligosaccharide of
- R 1 to R 4 are independently selected from each other and independently for each rhamnose unit and / or glycuronic acid as hydroxy, alkyloxy, carboxy, alkoxycarbonyl, acyloxy, sulfate or phosphate; or an -OCH 2 R a group , wherein R a is hydroxy, alkyloxy, acyloxy, sulfate or phosphate;
- n is an integer less than or equal to 50 and is chosen so that the molecular weight is greater than or equal to 5,000 Daltons and less than or equal to 100,000 Daltons;
- the oligosaccharides according to the present invention have never been described before. These compounds make it possible to maintain the integrity and concentration of the constituent molecules of the extracellular matrix by promoting their synthesis and their organization, and by limiting their degradation. These compounds can therefore be used to induce the biosynthesis and / or the organization of the constituent molecules of the extracellular matrix, and / or to reduce their degradation, thus allowing the establishment and maintenance of the architecture of the extracellular matrix and thus to prevent and / or treat the signs of intrinsic and / or extrinsic cutaneous and / or capillary aging, in particular the alteration of cutaneous and / or capillary structures and functions, the alteration of the tissue regeneration, the tissue relaxation, alteration of cutaneous and / or capillary microcirculation, alteration of cutaneous detoxification, loss of uniformity, brightness and shine of the dye (cutaneous and / or capillary), alteration of the cutaneous surface texture (appearance of wrinkles, puffiness, dry skin, etc.) and / or capillary (brittle hair),
- molecular weight refers indifferently to the molecule alone or to the mixture of molecules and then represents in this case a mean value
- Glycuronic acid means glucuronic acid or iduronic acid (which is found in a small proportion);
- pharmaceutically acceptable salt means any addition salt with a mineral or organic acid by the action of such an acid in an organic or aqueous solvent such as an alcohol, a ketone, an ether or a solvent chlorine, which is acceptable from a pharmaceutical point of view.
- salts By way of example of such salts, mention may be made of the following salts: benzenesulphonate, hydrobromide, hydrochloride, citrate, ethanesulphonate, fumarate, gluconate, iodate, isethionate, maleate, methanesulphonate, methylene-bis-b-oxynaphthoate, nitrate, oxalate, palmoate, phosphate, salicylate, sulfate, tartrate, theophyllinacetate and p-toluenesulfonate;
- an alkyl group is understood to mean a saturated, monovalent, linear or branched hydrocarbon-based chain containing from 1 to 6 carbon atoms, such as the following groups: methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, hexyl;
- alkyl retains the same definition when it includes the name of a group, for example in the alkyloxy group.
- alkyloxy groups there may be mentioned methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, pentyloxy;
- a "concentration under reduced pressure” step means a step for evaporating the water contained in an extract at a pressure of 50 to 100 mmHg and at a temperature ranging from 40 to 50 ° C.
- the subject of the present invention is an oligosaccharide of general formula (I) as defined above in which the substituents R 1 to R 4 are chosen independently of each other and independently for each rhamnose unit and / or glycuronic acid as being a hydroxy, alkyloxy, acyloxy, sulfate or phosphate group; or a group -OCH 2 R a , R a being as defined above.
- the subject of the present invention is an oligosaccharide of general formula (I) as defined above in which the substituents R 1 to R 4 are chosen independently of each other and independently for each rhamnose unit and or glycuronic acid as a hydroxy group or a sulfate group.
- the oligosaccharides of general formula (I) as defined above have a molecular weight greater than or equal to 5,000 Daltons and less than or equal to 100,000 Daltons.
- the subject of the present invention is an oligosaccharide of general formula (I) as defined above in which n is chosen so that the molecular weight is greater than or equal to 5,000 Daltons and less than or equal to 50,000 Daltons, preferably greater than or equal to 5,000 Daltons and less than or equal to 30,000 Daltons.
- n is chosen so that the molecular weight is greater than or equal to 5,000 Daltons and less than or equal to 25,000 Daltons, preferably greater than or equal to 5,000 Daltons and less than or equal to 15,000 Daltons.
- the oligosaccharides according to the present invention are prepared by radical degradation of polysaccharides extracted with Ulva Lactuca.
- the subject of the present invention is therefore a process for preparing oligosaccharides as defined above, comprising the following steps:
- the low molecular weight molecules can be purified by:
- the degradation method according to the present invention makes it possible to obtain oligosaccharides of low molecular weight with a high production yield, of the order of 25% relative to the dry weight of Ulva Lactuca seaweed powder used.
- Step a) of the degradation process according to the present invention consists of the dispersion of the Ulva lactuca seaweed powder in water.
- the dissolution is carried out with stirring at a speed ranging from 500 to 2500 rpm, preferably from 1000 to 2000 rpm.
- the dissolution is carried out at a temperature of from 20 ° C to 100 ° C, preferably at a temperature of from 40 ° C to 90 ° C, more preferably at a temperature of from 50 to 80 ° C.
- the pH of the solution can vary from 4 to 8, preferably the pH of the solution varies from 5 to 7.5.
- any means known to those skilled in the art can be used.
- 5N sodium hydroxide or 5N potassium hydroxide will be added.
- the concentration of polysaccharides in the water after dissolution may vary according to the needs of those skilled in the art and the equipment used.
- the polysaccharide concentration may be from 1 to 1000 g / l, more preferably from 1 to 100 g / l, most preferably from 10 to 50 g / l.
- Step b) of the degradation process according to the present invention consists of the gradual addition of hydrogen peroxide.
- the weight ratio between the Ulva lactuca extract and the added hydrogen peroxide is 1/1.
- the added hydrogen peroxide will preferably be selected as 35% H 2 0 2 .
- the addition of hydrogen peroxide is done gradually.
- the addition of hydrogen peroxide will be continuous over a period of from 30 minutes to 5 hours.
- the addition of hydrogen peroxide is carried out at a temperature ranging from 20 ° C. to 100 ° C., preferably at a temperature ranging from 40 ° C. to 90 ° C., more preferably at a temperature ranging from 50 ° to 80 ° C. ° C.
- the pH of the solution can vary from 4 to 8, preferably the pH of the solution varies from 5 to 7.5.
- any means known to those skilled in the art can be used.
- 5N sodium hydroxide or 5N potassium hydroxide will be added.
- Step c) of the degradation process according to the present invention consists of stirring the mixture extracted from Ulva / actwca / hydrogen peroxide.
- the agitation is carried out at a speed ranging from 100 to 2000 rpm, more preferably at a speed ranging from 300 to 1000 rpm.
- agitation will be maintained for a period of from 30 minutes to 5 hours, more preferably for a period of from 30 minutes to 3 hours, most preferably for a period of from 1 hour to 2 hours.
- the stirring is carried out at a temperature of from 20 ° C to 100 ° C, preferably at a temperature of from 40 ° C to 90 ° C, more preferably at a temperature of from 50 to 80 ° C.
- the pH of the solution can vary from 4 to 8, preferably the pH of the solution varies from 5 to 7.5.
- any means known to those skilled in the art can be used.
- 5N sodium hydroxide or 5N potassium hydroxide will be added.
- Step d) of the degradation process according to the present invention consists of a filtration or centrifugation step to remove the insoluble particles from the solution.
- the filtration of the medium will be carried out on diatom by frontal filtration.
- the medium will be centrifuged for 10 minutes at 10,000 g and at room temperature.
- Step e) of the degradation process according to the present invention consists of a step of concentration of the medium by evaporation of the water present in the extract. To carry out this concentration, any means known to those skilled in the art can be used. Preferably, this step will proceed under a pressure ranging from 50 and 100 mmHg, and at a temperature ranging from 40 to 50 ° C.
- Step f) of the degradation process according to the present invention consists of the purification of oligosaccharides of low molecular weight by:
- the degradation method according to the present invention can be conducted in the absence or in the presence of a catalyst.
- the method of degradation according to the present invention may be conducted in the presence of a catalyst selected from divalent cations such as for example Cu 2+ or Fe 2+ .
- the catalyst may be added in step b), c) or d) of the process according to the invention.
- the degradation method according to the present invention makes it possible to obtain low molecular weight molecules with a high production yield, of the order of 20 to 25% relative to the dry weight of Ulva lactuca powder used.
- the oligosaccharides according to the present invention can therefore be used in cosmetics to induce the biosynthesis and / or the organization of the constituent molecules of the extracellular matrix, and / or to reduce their degradation, thus enabling the establishment and maintenance of the architecture of the extracellular matrix and thus to prevent and / or treat the signs of intrinsic and / or extrinsic cutaneous and / or capillary aging, in particular the alteration of the structures and cutaneous and / or capillary functions, the alteration of the regeneration tissue, tissue relaxation, alteration of cutaneous and / or capillary microcirculation, alteration of cutaneous detoxification, loss of uniformity, brightness and shine of dye (cutaneous and / or capillary).
- the alteration of the cutaneous surface texture (appearance of wrinkles, puffiness, dry skin, etc.) and / or capillary (brittle hair), and the alteration n cutaneous and / or capillary architecture (inducing in particular hair loss).
- the subject of the present invention is therefore also the cosmetic use of one or more oligosaccharides according to the present invention as an agent for the prevention and / or treatment of the intrinsic and / or extrinsic signs of skin and / or capillary aging, in particular the alteration of cutaneous and / or capillary structures and functions, alteration of tissue regeneration, tissue loosening, alteration of cutaneous and / or capillary microcirculation, alteration of cutaneous detoxification, loss of uniformity , brightness and shine of the hue (cutaneous and / or capillary), the alteration of the cutaneous surface texture (appearance of wrinkles, puffiness, dry skin, etc.) and / or capillary (brittle hair ), and the alteration of the cutaneous and / or capillary architecture (inducing in particular the hair loss).
- the present invention also relates to a cosmetic composition
- a cosmetic composition comprising, as active principle, one or more oligosaccharides of low molecular weight as described above.
- the compositions according to the present invention may be formulated in any dosage form suitable for their administration.
- the compositions according to the present invention can thus be formulated in the form of cream, gel, lotion, milk, oil-in-water emulsion or water-in-oil, solution, ointment, spray, body oil, aftershave, soap, lip protection stick. , stick and pencil for makeup.
- compositions according to the present invention contain one or more oligosaccharides according to the present invention at contents ranging from 0.005% to 75% by total weight of the composition, preferably from 0.01% to 25%, preferentially still from 0.1% to 5%.
- one or more low molecular weight oligosaccharides according to the present invention or one or more of their pharmaceutically acceptable salts are mixed with the excipients conventionally used in the cosmetics field.
- compositions according to the present invention may take the form of a cream in which one or more low molecular weight oligosaccharides according to the present invention or one or more of their pharmaceutically acceptable salts are associated with excipients commonly used in cosmetology.
- compositions according to the present invention may take the form of gels in suitable excipients such as cellulose esters or other gelling agents, such as carbopol, sepinov (polyacrylate), guar gum, and the like.
- suitable excipients such as cellulose esters or other gelling agents, such as carbopol, sepinov (polyacrylate), guar gum, and the like.
- compositions according to the present invention may also take the form of a lotion or solution in which one or more low molecular weight oligosaccharides according to the present invention or one or more of their pharmaceutically acceptable salts are in encapsulated form.
- the microspheres according to the invention may for example consist of fatty substance, agar and water.
- One or more low molecular weight oligosaccharides according to the present invention or one or more of their pharmaceutically acceptable salts may be incorporated in liposomes, glycospheres, cyclodextrins, in chylomicrons, macro-, micro-nano-particles and as macro-, micro- and nanocapsules and also be absorbed on powdery organic polymers, talcs, bentonites and other mineral carriers.
- These emulsions have good stability and can be stored for the time necessary for use at temperatures between 0 and 50 ° C without sedimentation of the constituents or phase separation.
- compositions according to the present invention may also contain additives or adjuvants customary in cosmetologies, such as, for example, antimicrobial agents or perfumes, but also extraction or synthetic lipids, gelling and viscosifying polymers, surfactants and emulsifiers, hydro- or liposoluble active ingredients, plant extracts, tissue extracts, marine extracts, synthetic actives.
- additives or adjuvants customary in cosmetologies such as, for example, antimicrobial agents or perfumes, but also extraction or synthetic lipids, gelling and viscosifying polymers, surfactants and emulsifiers, hydro- or liposoluble active ingredients, plant extracts, tissue extracts, marine extracts, synthetic actives.
- compositions according to the present invention may also comprise other complementary active ingredients chosen for their action, for example for the slimming effect, the anti-cellulite effect, the firming effect, the moisturizing effect, the anti-cellulite effect, age, antimicrobial activity, antioxidant activity, anti-radical activity, healing effect, tensor effect, anti-wrinkle effect, chelating activity, complexing and sequestering activity, the soothing effect, the concealer effect, the anti-redness effect, the emollient activity, the hair conditioner effect, the anti-dandruff activity, the stimulating effect of the regrowth of the hair, the effect inhibiting hair loss, capillary gaining effect, depilatory activity, hair regrowth limiting activity, activity participating in cell renewal, activity modulating the inflammatory response, activity involved in maintaining the hair, oval of the face, but also the sun protection, has anti-irritant activity, cellular nutrition, cellular respiration, anti-seborrheic treatments, skin tone, hair protection.
- other complementary active ingredients chosen for their action,
- compositions according to the present invention contain complementary active ingredients, these are generally present in the composition at a sufficiently high concentration so that they can exercise their activity.
- compositions according to the present invention are preferably used daily and applied one or more times per day.
- compositions according to the present invention are very well tolerated, they exhibit no toxicity and their application to the skin for prolonged periods of time does not imply any systematic effect.
- the compositions according to the present invention can therefore be used to induce the biosynthesis and / or the organization of the constituent molecules of the matrix. extracellular, and / or to reduce their degradation, thus enabling the establishment and maintenance of the architecture of the extracellular matrix and thus prevent and / or treat intrinsic and / or extrinsic signs of skin and / or capillary aging.
- alteration of cutaneous and / or capillary structures and functions including alteration of tissue regeneration, tissue relaxation, alteration of cutaneous and / or capillary microcirculation, alteration of cutaneous detoxification, loss of uniformity, brightness and shine of the dye (cutaneous and / or capillary), the alteration of the cutaneous surface texture (appearance of wrinkles, puffiness, dry skin, etc.) and / or capillary (brittle hair), and the alteration of the cutaneous and / or capillary architecture (inducing in particular the hair loss).
- the extraction of the polysaccharides is carried out by dispersing 50 grams of Ulva lactuca seaweed powder in 1 liter of water at 95 ° C. with vigorous stirring (1000 rpm) for 2 hours. The mixture is then diatom-filtered (50 g) on a sintered glass 1. (Removal of the algae can also be carried out by centrifugation (10000 g, 30 minutes, 22 ° C.)). The Ulva lactuca extract is then precipitated in 3 volumes of 96 ° ethanol (at 4 ° C.) with stirring (500 rpm) for 2 hours.
- the precipitate is recovered on a filter cloth (porosity 500 ⁇ ) then washed with 100 ml of ethanol 96 °, drained and dried (at 40 ° C for 15 hours). Finally, the precipitate is ground and sieved over 500 ⁇ in order to obtain a fine powder of polysaccharides extracted from Ulva Lactuca.
- the temperature of the medium is allowed to return to 25 ° C and then filtered through diatomaceous earth (or centrifuged at 10,000g, 30 minutes, 25 ° C) to remove the insolubles.
- the filtrate is then concentrated under reduced pressure at 40 ° C. to a volume corresponding to 1/4 of the initial volume.
- the concentrate is then precipitated in 5 volumes of ethanol 96 ° at 4 ° C with stirring (500 rpm) for 2 hours.
- the precipitate is recovered by filtration on sintered glass 3 (porosity ⁇ 100 microns), triturated and then washed with 50 ml of ethanol for 30 minutes and then filtered on Sintered glass 3. Finally, the precipitate is dried in an oven (40.degree. 15 hours) and then ground into fine powder.
- the production yield of oligosaccharides of low molecular weight is 80%.
- the hydrolysis of the oligosaccharides is carried out with TF A 2N.
- the constituent sugars are analyzed by ion chromatography (HPAEC) with reference to monosaccharide databases (glucuronic acid, Rhamnose) for identification. Determination of molecular weight
- the determination of the sulfate level was carried out according to the turbidimetric barium / gelatin method of Dodgson and Price (1962). % relative Molecular weight (majority)
- the polysaccharide extract of Ulva lactuca is stirred vigorously (1000 rpm) at 80 ° C. and pH 7-7.5.
- To the medium is added 60 ml of a 35% H 2 O 2 solution for 1 hour at a flow rate of 1 ml / min at 60 ° C and maintaining at pH 7-7.5 by addition of NaOH (5M).
- the filtrate is then concentrated under reduced pressure at 40 ° C. to a volume corresponding to 1/5 of the initial volume.
- the concentrate is then precipitated in 5 volumes of ethanol 96 ° at 4 ° C with stirring (500 rpm) for 1 hour.
- the precipitate obtained is recovered by filtration on sintered glass 3 (porosity ⁇ 100 microns), triturated and then washed with 50 ml of ethanol 96 ° for 30 minutes and then filtered on sintered glass 3.
- the precipitate is dried in an oven (40 ° C., 15 hours) and then ground to a fine powder.
- the production yield of low molecular weight oligosaccharides is 80%.
- the hydrolysis of the oligosaccharides is carried out with 2N TFA.
- the constituent sugars are analyzed by ion chromatography (HPAEC) with reference to monosaccharide databases (glucuronic acid, Rhamnose) for identification.
- HPAEC ion chromatography
- the determination of the sulfate level is carried out according to the turbidimetric barium / gelatin method of Dodgson and Price (1962).
- EXAMPLE 3 Production of oligosaccharides according to the invention continuously and purification by Ultra Tangential Filtration 50 g of powder of algae of Ulva lactuca are dispersed in 1 liter of water at 90 ° C. with vigorous stirring (1000 rpm) during 2 hours. Then 60 ml of 35% H 2 O 2 solution was added to the medium for 1 hour at a flow rate of 1 ml / min at 80 ° C and maintained at pH 5-8 by addition of NaOH (5M). After complete addition of H2O2 (in 1 hour), stirring is maintained for 3 hours (500 rpm) at 80 ° C and pH 5-8. The mixture is then heat-filtered on diatom (50 g) on sintered glass 1. The elimination of the insoluble particles can also be carried out by centrifugation (10000 g, 15 minutes, 22 ° C.).
- the filtrate is then concentrated by tangential ultrafiltration on a membrane of 5 kilodaltons until a concentrated extract with 10% dry matter is obtained.
- the concentrate is finally atomized into a fine powder of oligosaccharides of low molecular weight.
- a transcriptomic study was carried out on human fibroblasts cultured in vitro in the absence or in the presence of oligosaccharides prepared according to Examples 1 to 3 at a concentration of 0.05% by weight (ie 0.05 g of oligosaccharides per 100 g of cell culture medium).
- both fibroblast cell cultures When both fibroblast cell cultures have reached confluence, their respective total ANs are extracted and then reverse transcribed into respective differentially labeled mono-stranded complementary (cDNA) DNAs (the cDNAs derived from the RNAs extracted from the fibroblasts grown in the control condition are labeled Cy3 cyanine and the cDNAs derived from the RNAs extracted from the fibroblasts cultured in the test condition are labeled with cyanine Cy5).
- cDNA mono-stranded complementary
- Both types of cDNA are pooled and hybridized on a DNA chip containing the 44,000 sequences of the human genome.
- the reading of the chip makes it possible to determine the overexpression (Cy5 labeling greater than the Cy3 labeling for the hybridized genetic sequence concerned) and the subexpression (Cy5 labeling less than the Cy3 labeling for the hybridized genetic sequence concerned) of the genes induced by the treatment of the genes.
- fibroblasts with oligosaccharides according to the present invention.
- the oligosaccharides used in particular cause the overexpression of the FGF1, CCNA2 and RHAMM genes and the under-expression of the ADAMTS, TMEM27 and ITH5 genes. All these genes encode the proteins bearing the same names and involved in the metabolism and the establishment of the constituent molecules of the extracellular matrix.
- the FGF1 and CCNA2 proteins allow the mobilization of fibroblasts and induce the stimulation of the biosynthesis, by these cells, of the two main types of constituent molecules of the extracellular matrix (collagens and hyaluronic acid).
- the RHAMM protein the latter coupled to the hyaluronic acid receptor participates in the fixation and organization of the latter thus allowing the establishment and maintenance of the architecture of the extracellular matrix.
- ADAMTS and TMEM27 genes induces the decrease in catabolism (degradation) of collagen molecules by inhibiting the activity of Matrix Metalloproteinases (MMPs).
- MMPs Matrix Metalloproteinases
- the subexpression of the ITH5 gene induces the inhibition of catabolism of hyaluronic acid.
- the transcriptomic study has made it possible to demonstrate that the compounds of the present invention allow the establishment and maintenance of the integrity of the extracellular matrix i) by inducing the biosynthesis of the collagen molecules and the hyaluronic acid (thanks to the overexpression of the FGF1 and CCNA2 genes), ii) by inhibiting the degradation of these constituent molecules (thanks to the under-expression of the ADAMTS, TMEM27 and ITH5 genes), iii) by promoting the fixation and the organization of the hyaluronic acid molecules (thanks to the overexpression of the RHAMM gene).
- the fibroblast cultures are established from skin of human foreskins harvested during circumcisions and are amplified in RPMI 1640 culture medium supplemented with fetal calf serum, L-glutamine and gentamicin. The tests are performed on fibroblasts, between the 2 nd and 4 th passage, in order to ensure reproducibility between different experiments.
- the fibroblasts are seeded in 25 cm 2 dishes at a rate of 10 6 cells per milliliter. They were then incubated for 24 hours in the absence (control condition) or in the presence of three concentrations of oligosaccharides of the present invention (conditions treated). • Bachelor Apr 24 hour incubation, fibroblasts were recovered by centrifugation and t are measured:
- the results obtained show that the oligosaccharides of the present invention induce an increase in the biosynthesis of the main constituent molecules of the extracellular matrix, namely collagens and hyaluronic acid. Also, these results demonstrate that these oligosaccharides of the present invention induce a decrease in the production of Matrix Metalloproteinases (MMP1 and MMP3) responsible for the degradation of collagen molecules.
- MMP1 and MMP3 Matrix Metalloproteinases
- oligosaccharides thus cause biosynthesis and prevent the degradation of the main constituent molecules of the extracellular matrix.
- the compounds of the present invention can therefore be used to induce the biosynthesis and / or organization of the constituent molecules of the extracellular matrix, and / or to reduce their degradation, thus enabling the establishment and maintenance of the the extracellular matrix and therefore to prevent and / or treat the signs of intrinsic and / or extrinsic cutaneous and / or capillary aging, in particular the alteration of cutaneous and / or capillary structures and functions, of the alteration of the tissue regeneration, tissue laxity, alteration of cutaneous and / or capillary microcirculation, alteration of cutaneous detoxification, loss of uniformity, brightness and shine of dye (cutaneous and / or capillary), the alteration of the cutaneous surface texture (appearance of wrinkles, puffiness, dry skin, etc.) and / or capillary (brittle hair), the alteration of the arch cutaneous and / or capillary itecture (inducing in particular hair loss).
- Example 6 Clinical Study on Human Volunteers A double-blind clinical study was carried out on 18 human volunteers (18 Caucasian women aged 56 ⁇ 6 years) in order to estimate, at the level of the face, the effects remodeling and re-sculting oligosaccharides according to the present invention.
- each volunteer applied, on one of its hemispheres, a cosmetic formulation containing 2% by weight of oligosaccharides according to the present invention (ie 2 g of oligosaccharides according to the present invention per 100 g of formulation) ; on its other hemi-face a placebo cosmetic formulation (formulation of identical composition but not containing oligosaccharides according to the present invention).
- the distribution of the hemispaces was performed in a randomized manner.
- the remodeling and re-sculting effects in the face were evaluated by two complementary techniques:
- the projection of fringes allows a direct and immediate acquisition of the morphology of the face in three dimensions and thus to evaluate its volume.
- This technique allows an evaluation of the reduction of the relaxation of the oval of the face (remodeling effect, re-scultant).
- the three-dimensional information is calculated by the deformation of the fringes projected on the surface of the face and recorded by a digital camera.
- the analysis consists of a superposition of images taken at different measurement times. Thus, a region of interest is defined at the level of sagging skin. This zone is located in the same place for all measurement times in the same subject. It makes it possible to calculate a volume between this zone of interest and its projection on a reference plane.
- the parameter analyzed is the relative volume of the jowls, expressed in mm 3 . A decrease in this parameter is synonymous with a remodeling effect of the tested product.
- the second technique used, ballistometry is based on the use of a mass impacting the surface of the skin.
- the biomechanical properties of the skin are then measured through skin-mass interactions.
- a vibrational motion is imposed on the skin and is recorded for 3 seconds then translated into electrical signals, then quantified and finally evaluated in terms of amplitude.
- the measurements therefore make it possible to evaluate skin firmness and elasticity.
- the measured parameters are:
- the indentation (in mm) corresponding to the peak recording height of penetration of the tip of the probe into the skin during the first impact.
- the indentation shows the resistance of the skin during the penetration of the probe, and thus allows an estimate of the firmness of the skin. The lower the indentation, the firmer the skin. Thus, a decrease in indentation reveals a firming effect;
- alpha (without unit) measures the damping energy.
- the alpha describes the rebound energy of the probe and therefore the density of the skin. More energy is strong, the more the skin is dense. Thus, an increase in alpha shows a denser skin;
- the area represents the bounces of the probe and therefore the softness (the flaccid aspect) of the skin: its relaxation.
- a decrease in the area reveals a reduction in relaxation (increased firmness).
- a resuscitating effect inducing a firming effect (decrease of the indentation parameter, measured by ballistometry), by improving the cutaneous density (increase of the alpha parameter, measured by ballistometry) and by decreasing the cutaneous relaxation (decrease of the parameter area, measured by ballistometry).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Sustainable Development (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1253197A FR2989087B1 (en) | 2012-04-06 | 2012-04-06 | NOVEL OLIGOSACCHARIDE COMPOUNDS AND THEIR COSMETIC USE |
PCT/FR2013/050756 WO2013150253A1 (en) | 2012-04-06 | 2013-04-05 | Novel oligosaccharide compounds and the cosmetic use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2833863A1 true EP2833863A1 (en) | 2015-02-11 |
Family
ID=48289447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13720456.6A Withdrawn EP2833863A1 (en) | 2012-04-06 | 2013-04-05 | Novel oligosaccharide compounds and the cosmetic use thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2833863A1 (en) |
JP (1) | JP6189928B2 (en) |
KR (1) | KR102029078B1 (en) |
FR (1) | FR2989087B1 (en) |
WO (1) | WO2013150253A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2999084B1 (en) * | 2012-12-11 | 2015-03-13 | Amadeite | EXTRACT OF ALGAE COMPRISING IN PARTICULAR SULFATED AND NON-SULFATED POLYANIONIC POLYSACCHARIDES AND USES THEREOF |
FR3020570B1 (en) * | 2014-04-30 | 2017-07-21 | Pierre Fabre Dermo-Cosmetique | ASSOCIATION OF A HYALURONIC ACID AND A SULFATE POLYSACCHARIDE |
FR3075644B1 (en) * | 2017-12-27 | 2020-08-28 | Oreal | SULPHATED OLIGOSACCHARIDES AND THEIR COSMETIC USES |
CN110183544A (en) * | 2019-06-06 | 2019-08-30 | 山东天易科技有限公司 | A kind of preparation method of algal polysaccharides |
CN110713626B (en) * | 2019-10-14 | 2021-06-01 | 福建农林大学 | Preparation method of ulva oligosaccharide compound with auxiliary anti-tumor effect |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH696838A5 (en) | 2007-05-29 | 2007-12-31 | Labo Cosprophar Ag | New cosmetic composition comprises Aosa alga or an extract, useful for sustaining relaxed skin tissue and/or with structural sagging and for relifting parts of the face or body |
-
2012
- 2012-04-06 FR FR1253197A patent/FR2989087B1/en active Active
-
2013
- 2013-04-05 EP EP13720456.6A patent/EP2833863A1/en not_active Withdrawn
- 2013-04-05 WO PCT/FR2013/050756 patent/WO2013150253A1/en active Application Filing
- 2013-04-05 JP JP2015503927A patent/JP6189928B2/en active Active
- 2013-04-05 KR KR1020147028486A patent/KR102029078B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
None * |
See also references of WO2013150253A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP6189928B2 (en) | 2017-08-30 |
KR20150002659A (en) | 2015-01-07 |
JP2015515524A (en) | 2015-05-28 |
WO2013150253A1 (en) | 2013-10-10 |
FR2989087A1 (en) | 2013-10-11 |
FR2989087B1 (en) | 2016-01-01 |
KR102029078B1 (en) | 2019-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1021161B1 (en) | Use of ellagic acid and its derivatives in cosmetics and dermatology | |
FR2929511A1 (en) | NEW ACTIVE PRINCIPLE STIMULATING THE PROLIFERATION AND / OR THE ACTIVITY OF FIBROBLASTS. | |
FR3018191A1 (en) | COSMETIC USES OF SWERTIAMARIN | |
WO2013150253A1 (en) | Novel oligosaccharide compounds and the cosmetic use thereof | |
WO1997006659A2 (en) | Use of an eriobotrya japonica extract | |
FR2973230A1 (en) | USE OF GINGERONE OR ITS DERIVATIVES TO DECREASE OR DELAY THE SIGNS OF SKIN AGING | |
EP3164197B1 (en) | Peptidic extracts of lupine and skin firmness | |
WO2011117547A1 (en) | Oligosaccharide extracted from halymenia durvillaei, method for preparing such an oligosaccharide, and cosmetic use of said oligosaccharide | |
WO2019069007A1 (en) | Process for using a let-7b inhibitor in cosmetics and/or nutraceuticals | |
FR2988606A1 (en) | TOPICAL COMPOSITION COMPRISING BIOACTIVE SULPHATE OLIGOSACCHARIDES AND COSMETIC USES | |
FR3075619A1 (en) | XYLOSIDE DERIVATIVES OF RESVERATROL FOR THEIR USE IN COSMETICS | |
FR2973381A1 (en) | New oligosaccharide compounds useful e.g. for maintaining the integrity of the constituent molecules in the extracellular matrix and for reducing the glycation and/or hyperkeratinization process | |
FR3055550B1 (en) | NOVEL ACTIVE IMMUNOMODULATOR AND COMPOSITION COMPRISING SAME | |
FR2946347A1 (en) | New 2-fluoro-2-(tetrahydro-pyran-2-yl)-malonic acid compounds are glucose transporter 1 inducers, useful to fight against the signs of skin aging and/or appendage, prevent wrinkles and fine lines and reduce and/or prevent hair loss | |
FR3011248A1 (en) | PROCESS FOR OBTAINING CLIOTED BIOACTIVE OLIGOSACCHARIDES, MICROORGANISM FOR ITS IMPLEMENTATION, OLIGOSACCHARIDES OBTAINED AND THEIR COSMETIC USE | |
FR2977158A1 (en) | Use of Bursera graveolens essential oil to prevent or treat signs of skin aging, fine lines and wrinkles, fighting against withered skin, soft skin or thin skin, and tightening the skin | |
FR3049461A1 (en) | USE OF A PLANT EXTRACT OF POUTERIA LUCUMA FRUIT IN A COSMETIC COMPOSITION | |
WO2020065213A1 (en) | Use of an agave extract for enhancing the barrier function of the skin, scalp and/or mucusa and modulating the skin microbiota | |
WO2019077268A1 (en) | Cosmetic composition for active prevention of the signs of ageing | |
EP2190403A1 (en) | Use of 2,2'-cyclolignanes for inducing, restoring or stimulating the pigmentation of the skin, hair or hairs | |
FR2971711A1 (en) | Use of extract of Einkorn wheat (Triticum monococcum), as active agent for activating synthesis of extracellular matrix protein of skin, in cosmetic composition comprising medium for fighting against the appearance of signs of skin aging | |
FR3075797B1 (en) | ASCROBIC 3-XYLOSIDE DERIVATIVES FOR THEIR COSMETIC USE | |
WO2023144487A1 (en) | Ingredient for protecting the skin and/or mucous membranes from virulence factors | |
FR3034989A1 (en) | COSMETIC COMPOSITIONS COMPRISING HYALURONIC ACID OLIGOMERS AND DEDIFFERENCED AND ELICITED BAGGING VEGETABLE CELLS ENCAPSULATING A SAFFRON EXTRACT | |
EP2183284A2 (en) | Cosmetic composition containing one or more compounds of the -(l,3)- glucuronane or -(l,3)-glucoglucuronane type |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20141003 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20180413 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200109 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200603 |